Overview
Indications
Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical. Enalaprilat injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. WARNINGS In using enalaprilat injection, consideration shou
Boxed Warning
FDA Black Box Warning
USE IN PREGNANCYWhen used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. WARNINGS , Fetal/Neonatal Morbidity and Mortality. When pregnancy is detected, enalaprilat injection should be discontinued as soon as possible. See
Contraindications
When this intervention should not be used
Enalaprilat injection is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
Clinical Trials
5 trials linked to this intervention
Recent Trials
Genetic Determinants of ACEI Prodrug Activation
Postpartum Evaluation of Nifedipine and Enalapril for Hypertension
Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
Effect of DPP4 Inhibition on Vasoconstriction
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Specialists
Providers who commonly manage this intervention
Health Goals
Goals connected through associated conditions
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Enalaprilat (substance)
- SNOMED CT
- 48052001
- UMLS CUI
- C0014027
- RxNorm CUI
- 3829
- Labeler
- Mayne Pharma (USA) Inc.
Clinical Data
This intervention maps to 16 entities in the Healos knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.